IRVINE, Calif., Nov. 12, 2010 /PRNewswire-FirstCall/ --
Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive
treatments for aortic disorders, announced today that a podium
presentation on the Company's Ventana™ fenestrated stent graft will
be given at the VEITHsymposium 2010 in New York by Daniel G.
Clair, MD, Chairman, Cleveland Clinic Department of Vascular
Surgery, Cleveland, OH, and
co-chair of the VEITHsymposium. Dr. Clair participated in the
first implant of the Ventana stent graft earlier this month and
will discuss the need for fenestrated stent grafts and the early
clinical experience with Ventana in his presentation titled
"Off-The-Shelf Fenestrated Device From Endologix For Treatment of
Pararenal And Juxtarenal AAAs: Initial Clinical Experience."
Date: Saturday,
November 20, 2010
|
|
Time: 12:54 p.m.
ET
|
|
Location:
VEITHsymposium 2010, Hilton New
York
|
|
Session: Luncheon
Lectures: New and Improved Endografts, Techniques and
Devices
|
|
Title: Off-The-Shelf Fenestrated Device
From Endologix For Treatment of Pararenal And Juxtarenal AAAs:
Initial Clinical Experience
|
|
Presenter:
Daniel G. Clair, MD
|
|
|
In addition, Endologix will be hosting several physician
presentations and hands-on product demonstrations at the Company's
pavilion at the VEITHsymposium. These presentations are focused on
Endologix's current and new product pipeline.
John McDermott, Endologix
President and Chief Executive Officer, said, "We are very pleased
that a number of thought leading physicians, including Dr. Clair,
will be presenting their experience with our products at the
VEITHsymposium next week. We believe we have the most
innovative new product pipeline in the aortic stent graft market,
the strength of which will be evident by the many presentations and
case demonstrations we have planned for the meeting. We look
forward to Dr Clair's presentation and sharing more information
about our new product pipeline with physicians in the months
ahead."
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship product is
the Powerlink® System, which is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening
of the wall of the aorta, the largest artery in the body, resulting
in a balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
Forward-Looking Statements
Except for historical information contained herein, this news
release contains forward-looking statements, including the planned
expansion of Endologix's product portfolio, the accuracy of which
are necessarily subject to risks and uncertainties, all of which
are difficult or impossible to predict accurately and many of which
are beyond the control of Endologix. Many factors may cause actual
results to differ materially from anticipated results, including
the approval and success of sales efforts for new products, product
research and development efforts, and other economic, business,
competitive and regulatory factors. The Company undertakes no
obligation to update its forward looking statements. Please refer
to the Company's Annual Report on Form 10-K for the year ended
December 31, 2009, and the Company's
other filings with the Securities and Exchange Commission, for more
detailed information regarding these risks and other factors that
may cause actual results to differ materially from those expressed
or implied.
|
|
|
|
|
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix, Inc.
|
The Ruth Group
|
|
John McDermott, CEO
|
Nick Laudico (646)
536-7030
|
|
(949) 595-7200
|
Zack Kubow (646)
536-7020
|
|
www.endologix.com
|
|
|
|
|
|
|
SOURCE Endologix, Inc.